EIKN
Eikon Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$7.70
+3.77%Next report
Analyst consensus
- Next report date
- Nov 12, 2026
- EPS estimate
- -$1.74
- Revenue estimate
- —
Latest reported
- Last report date
- Aug 13, 2026
- EPS actual
- -$1.63
- EPS estimate
- -$1.58
- Revenue actual
- —
- Revenue estimate
- —
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 0
- EPS misses (12Q)
- 2
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- -28.5%
- Revenue beats (12Q)
- —
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $14
- PT range
- $4.00 – $23
- Analysts
- 2
1 Buy0 Hold1 Sell
No earnings call summaries available
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Aug 13, 2026 | -$1.58 | -$1.63 | Miss -3.16% | — |
| May 11, 2026 | -$1.60 | -$2.46 | Miss -53.75% | — |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 12, 2026